Physician profile
Robert Patitucci
NPI 1902807480
$4,456.25
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,159 · 2020: $920 · 2021: $1,566 · 2022: $811.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,085.02 | 2019-2022 | |
| Glaxosmithkline, LLC. | $523.95 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $378.23 | 2019-2022 | |
| Abbvie INC. | $344.61 | 2021-2022 | |
| Amgen INC. | $224.30 | 2019-2022 | |
| Allergan, INC. | $174.04 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $169.33 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $153.06 | 2019-2021 | |
| Esperion Therapeutics, INC. | $135.57 | 2020-2021 | |
| Pfizer INC. | $128.84 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.80 | 2022 | |
| Philips North America LLC | $92.82 | 2019-2021 | |
| Indivior INC. | $91.67 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.88 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.19 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $77.21 | 2019-2022 | |
| Amarin Pharma, INC. | $72.52 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $57.70 | 2020-2022 | |
| Alkermes, INC. | $56.32 | 2021 | |
| Lilly USA, LLC | $55.75 | 2019-2022 | |
| Dexcom, INC. | $51.06 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $44.60 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.38 | 2022 | |
| Lundbeck LLC | $29.26 | 2021-2022 | |
| Nalpropion Pharmaceuticals LLC | $28.24 | 2019 | |
| Eisai INC. | $26.83 | 2019 | |
| Gilead Sciences, INC. | $25.99 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.12 | 2022 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Abbott Laboratories | $15.93 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.99 | 2020 | |
| Daiichi Sankyo INC. | $13.60 | 2021 | |
| Seqirus USA INC | $13.17 | 2022 | |
| Sanofi Pasteur INC. | $13.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.22 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Patitucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.